In certain men newly diagnosed with Advanced Prostate Cancer, or metastatic prostate cancer debunking the tumor with radiation can increase survival advantage.
Developing or being diagnosed with Prostate Cancer and having bone metastases is not good news.
Since the approvals for the early use of docetaxel chemotherapy (Taxotere) and the early use of abiraterone acetate (Zytiga) there is no clear evidence demonstrating which of these two agents should be used for men with hormone sensitive, newly diagnosed, aggressive prostate cancer.
In a surprising analysis it was determined that the overall survival (OS) between African American and Caucasian men with metastatic castration-resistant prostate cancer (mCRPC) favors African Americans!
There was a large meta-analysis recently published that compared the efficacy of abiraterone acetate (Zytiga), enzalutamide (Xtandi), cabazitaxel (Jevtana) and Radium-223 (Xofigo) in the treatment of castration-resistant, docetaxel-resistant metastatic prostate cancer.
Treatment modalities vary for men diagnosed with pathologic lymph node-positive (pN1) prostate cancer. Understanding current treatment patterns and their outcomes can help provide you with insight and direction in your decision-making.